MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
June 25, 2010
Brian Orelli
Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review. mark for My Articles similar articles
The Motley Fool
July 13, 2010
Brian Orelli
A Triple Delight: 3 Stocks All Up More Than 10% What's good for the obese goose is good for the gander when it comes to new drug treatments for losing weight. mark for My Articles similar articles
The Motley Fool
September 17, 2010
Brian Orelli
Thanks for Nothing, Fen-Phen Arena gets knocked down despite a relatively clean side-effect profile. mark for My Articles similar articles
The Motley Fool
September 21, 2010
Brian Orelli
Double-Digit Weight Loss, Double-Digit Share Increase Vivus is down, but apparently not out. mark for My Articles similar articles
The Motley Fool
October 19, 2010
Brian Orelli
Why the FDA Won't Approve Lorcaserin and Qnexa (Yet) Obesity drugs get their day in front of the agency. mark for My Articles similar articles
The Motley Fool
September 16, 2010
Brian Orelli
Abbott's Product Line May Get Thinner Not that it needs the obesity drug. mark for My Articles similar articles
The Motley Fool
December 31, 2010
Brian Orelli
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. mark for My Articles similar articles
The Motley Fool
October 25, 2010
Brian Orelli
Arena's Boring News The Food and Drug Administration turned down Arena Pharmaceuticals' obesity drug, lorcaserin. Tell us something we didn't know. mark for My Articles similar articles
The Motley Fool
September 14, 2010
Brian Orelli
42% Drop? Really? Tell Us Something We Didn't Know. Arena Pharmaceuticals gets knocked down for no good reason. mark for My Articles similar articles
The Motley Fool
September 9, 2009
Brian Orelli
Weight Down. Stock Price Up. Really Up. Positive phase 3 trials will do that for VIVUS' anti-obesity drug, Qnexa mark for My Articles similar articles
The Motley Fool
October 11, 2010
Brian Orelli
What Meridia's Demise Means for Arena, VIVUS, and Orexigen Safety first ... and second ... and third... mark for My Articles similar articles
The Motley Fool
June 3, 2011
Brian Orelli
FDA Bullies Obesity Drugmakers It's been clear for some time that the Food and Drug Administration isn't particularly fond of obesity drugs. Now it's just being a bully. mark for My Articles similar articles
The Motley Fool
December 12, 2008
Brian Orelli
The Skinny on the Latest Drug Trial VIVUS' obesity treatment data looks good, but will its drug be a marketing success? mark for My Articles similar articles
The Motley Fool
September 2, 2010
Luke Timmerman
Orexigen Nabs $1B Deal With Takeda to Market Obesity Drug, Shares Climb San Diego-based Orexigen Therapeutics has found a partner to help it compete in the growing market for drugs to combat obesity, Japan-based Takeda Pharmaceutical. mark for My Articles similar articles
The Motley Fool
May 4, 2011
Brian Orelli
VIVUS Unveils Its Obesity Plans Investors are getting fat on the news that VIVUS has a plan, and a backup plan, to get its obesity drug Qnexa on the market. mark for My Articles similar articles
The Motley Fool
February 1, 2011
Brian Orelli
Orexigen Falls Short Its obesity drug fails in the final mile of the drug-development marathon. mark for My Articles similar articles
The Motley Fool
July 16, 2010
Tom Hughes
Lessons Learned About the Outlook for New Obesity Drug Approval The recent FDA advisory committee meeting on Vivus' weight loss pill proved to us, once again, how incredibly difficult it is to successfully develop and register new drugs for obesity. mark for My Articles similar articles
The Motley Fool
July 16, 2010
Luke Timmerman
Vivus Obesity Drug Shot Down by FDA Panel Vivus suffered a setback today at an important meeting for the future of obesity drug development, with implications for Arena Pharmaceuticals and Orexigen Therapeutics. mark for My Articles similar articles
The Motley Fool
September 18, 2009
Brian Orelli
Up, Down, Up. Is This Stock a Home Run or Not? Shares of Arena Pharmaceuticals have been on a roller coaster after word that the company would release data for its obesity drug. mark for My Articles similar articles
The Motley Fool
December 3, 2010
Brian Orelli
Obesity Drug Companies Are (Still) Risky Orexigen heads before an FDA panel. mark for My Articles similar articles
The Motley Fool
April 5, 2011
Brian Orelli
Obese Expectations Trump Great Data Sorry VIVUS and Orexigen, you're still not going to get your drugs approved quickly. mark for My Articles similar articles
The Motley Fool
November 9, 2010
Brian Orelli
Arena Pharmaceuticals Scores Some Points Overall, the recent Bloom-DM study leaves Arena in a slightly better position than it was in before the data was released, but this battle to get lorcaserin approved is far from over. mark for My Articles similar articles
The Motley Fool
December 8, 2010
Brian Orelli
Up 100% With Room to Fly Orexigen gets a positive FDA panel nod. mark for My Articles similar articles
The Motley Fool
July 14, 2010
Luke Timmerman
Vivus Faces Turning Point Tomorrow Thursday's the big day. All eyes will be on Vivus and the FDA's decision on their new obesity drug mark for My Articles similar articles
The Motley Fool
September 2, 2010
Brian Orelli
Fatter Wallet. Up 22%. Still Risky. After VIVUS' Qnexa was shot down at its FDA advisory panel, it's clear that Arena and Orexigen have an uphill battle in front of them. mark for My Articles similar articles
The Motley Fool
January 4, 2012
Brian Orelli
This Biotech's Obese To-Do List Is Done Arena resubmits lorcaserin for FDA approval. mark for My Articles similar articles
Chemistry World
September 17, 2010
Andrew Turley
Obesity drugs strive for US approval Could 2010 yet be the year of the obesity drug? At first glance the signs are promising. Regulators in the US will soon decide whether to allow three new contenders onto this attractive market. mark for My Articles similar articles
The Motley Fool
June 3, 2011
Luke Timmerman
Orexigen, Facing High Hurdle at FDA, Puts Obesity Drug Development on Hold The close attention paid to safety makes this drug difficult to get right. mark for My Articles similar articles
The Motley Fool
September 14, 2010
Luke Timmerman
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. mark for My Articles similar articles
The Motley Fool
November 23, 2009
Brian Orelli
The Side Effect of Developing Obesity Drugs The FDA is fickle when it comes to weight-loss drugs. mark for My Articles similar articles
The Motley Fool
March 30, 2009
Brian Orelli
Hopes Fall Short for Arena Pharmaceuticals Arena Pharmaceuticals' obesity drug lorcaserin doesn't look like it's doing enough to be a marketing success -- and the results might not even be enough to get it past the Food and Drug Administration. mark for My Articles similar articles
The Motley Fool
December 22, 2010
Brian Orelli
Arena Charges On It seems Fool readers were a little more optimistic about the timing of Arena Pharmaceuticals' resubmission of its obesity drug to the Food and Drug Administration than the company is. mark for My Articles similar articles
The Motley Fool
June 1, 2011
Brian Orelli
Not All "Regulatory Updates" Are the Good Kind Orexigen gives an update; investors update their holdings. mark for My Articles similar articles
The Motley Fool
March 8, 2010
Brian Orelli
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. mark for My Articles similar articles
The Motley Fool
January 31, 2011
Brian Orelli
5 Drugmakers Headed Back to the Drawing Board Sometimes an FDA rejection is more of a to-do list. mark for My Articles similar articles
The Motley Fool
September 21, 2011
Brian Orelli
Obesity-Drug Makers Stop Getting Bullied The drugs are still relative long shots being developed by companies that may have to raise more cash between now and an approval. mark for My Articles similar articles
The Motley Fool
November 12, 2010
Brian Orelli
Benlysta: Not Perfect, but Good Enough Human Genome should get past the FDA advisory panel next week. mark for My Articles similar articles
The Motley Fool
September 16, 2011
Brian Orelli
A Shrinking Obesity Market VIVUS figures some sales are better than none for its obesity drug Qnexa. mark for My Articles similar articles
The Motley Fool
May 27, 2008
Brian Orelli
Livin' la Vivus Loca Irrational Exuberance for Vivus' Lead Drug Candidate? mark for My Articles similar articles
The Motley Fool
July 20, 2007
Brian Orelli
Arena Keeps Burning the Cash The pipeline drugs being developed by Arena Pharmaceuticals hold promise, but it will be a while before, or if, the company shows a profit. mark for My Articles similar articles
The Motley Fool
November 29, 2007
Brian Lawler
Another Chapter in Glaxo's Relenza Saga An FDA advisory panel suggested that the Relenza label should be strengthened to include the possibility of abnormal behavior and hallucinations in those who take it. mark for My Articles similar articles
The Motley Fool
April 1, 2008
Brian Lawler
VIVUS' New Old Drugs The small company finds plenty of help as it tries to get its anti-obesity drug to market. mark for My Articles similar articles
The Motley Fool
October 3, 2008
Brian Orelli
Merck Can't Fight the Munchies The pharma gives up on its anti-obesity drug. mark for My Articles similar articles
The Motley Fool
December 3, 2010
Travis Hoium
Orexigen Therapeutics Shares Plunged: What You Need to Know Shares of biopharmaceutical company Orexigen Therapeutics fell 10% today after a Food and Drug Administration announcement. mark for My Articles similar articles
The Motley Fool
August 17, 2007
Brian Orelli
Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully. mark for My Articles similar articles
The Motley Fool
August 31, 2009
Brian Orelli
Good Luck, Genzyme -- You'll Need It The drugmaker faces an FDA advisory-panel showdown regarding its leukemia drug Clolar. mark for My Articles similar articles
The Motley Fool
December 14, 2005
Stephen D. Simpson
Arena Fattens Wallets Positive phase 2 data sends the biotech's stock up big and raises hopes of a blockbuster. mark for My Articles similar articles
The Motley Fool
June 29, 2010
Brian Orelli
The Final Obstacle to Your Drug Company Multibagger The dreaded FDA advisory committee meeting. mark for My Articles similar articles
The Motley Fool
August 10, 2010
Brian Orelli
When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow. mark for My Articles similar articles
Chemistry World
July 18, 2012
Andrew Turley
Obesity drug approved in US US regulators have approved a new obesity treatment. Qsymia (phentermine, topiramate) tablets have been approved for overweight adults as part of a regimen that includes a low calorie diet and exercise. mark for My Articles similar articles